We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$5.12B
1-Year Est. Return
314.02%
This Fund
S&P 500
This Quarter
Est. Return
+26.22%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$1.23B
AUM Growth
+$240M
(+24%)
Cap. Flow
+$116M
Cap. Flow
% of AUM
9.38%
Top 10 Holdings %
Top 10 Hldgs %
61.25%
Holding
137
New
51
Increased
28
Reduced
20
Closed
23
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ONXX
ONYX PHARMACEUTICALS INC
ONXX
|
+$70.5M |
| 2 |
CELG
Celgene Corp
CELG
|
+$37.6M |
| 3 |
RPRX
Repros Therapeutics Inc.
RPRX
|
+$27.9M |
| 4 |
TSRO
TESARO, Inc.
TSRO
|
+$21.7M |
| 5 |
QCOR
QUESTCOR PHARMA INC
QCOR
|
+$19.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AEGR
Aegerion Pharmaceuticals
AEGR
|
+$106M |
| 2 |
Biogen
BIIB
|
+$49.8M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$31.3M |
| 4 |
STML
Stemline Therapeutics, Inc.
STML
|
+$16.4M |
| 5 |
Neurocrine Biosciences
NBIX
|
+$11.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 76.94% |
| 2 | Financials | 0.01% |
| 3 | Consumer Staples | 0.01% |
| 4 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AEGR
1
DELISTED
Aegerion Pharmaceuticals
AEGR
| $200M | 16.2% |
2,328,341
-1,245,085
| -35% | -$106M |
|
2
Sarepta Therapeutics
SRPT
$1.62B
| $131M | 10.62% |
2,772,069
+49,981
| +2% | +$1.92M |
|
|
ONXX
3
DELISTED
ONYX PHARMACEUTICALS INC
ONXX
| $69.5M | 5.64% |
+556,944
| New | +$70.5M |
|
4
Talphera
TLPH
$67.5M
| $63.2M | 5.13% |
292,920
+42,500
| +17% | +$9.27M |
|
|
TSRO
5
DELISTED
TESARO, Inc.
TSRO
| $58.6M | 4.76% |
1,513,644
+593,150
| +64% | +$21.7M |
|
|
CELG
6
DELISTED
Celgene Corp
CELG
| $56.2M | 4.56% |
729,238
+536,726
| +279% | +$37.6M |
|
7
Gilead Sciences
GILD
$166B
| $54.3M | 4.41% |
864,070
+75,710
| +10% | +$4.52M |
|
|
8
Neurocrine Biosciences
NBIX
$18.3B
| $48.3M | 3.92% |
4,270,704
-811,013
| -16% | -$11.1M |
|
|
RPRX
9
DELISTED
Repros Therapeutics Inc.
RPRX
| $39.7M | 3.22% |
1,481,733
+1,300,303
| +717% | +$27.9M |
|
10
Vertex Pharmaceuticals
VRTX
$124B
| $34.3M | 2.78% |
452,095
+195,548
| +76% | +$15.6M |
|
11
PUT
iShares Biotechnology ETF
IBB
$9.51B
| $30.4M | 2.46% |
+434,400
| New | +$28.5M |
|
|
QCOR
12
DELISTED
QUESTCOR PHARMA INC
QCOR
| $21.8M | 1.77% |
376,350
+334,164
| +792% | +$19.9M |
|
|
EXAS
13
DELISTED
Exact Sciences
EXAS
| $20.6M | 1.67% |
1,748,314
+98,756
| +6% | +$1.27M |
|
14
Viatris
VTRS
$20.8B
| $17.6M | 1.43% |
+460,305
| New | +$16.2M |
|
15
Cigna
CI
$78.9B
| $17.1M | 1.39% |
222,848
+222,558
| +76,744% | +$17.4M |
|
|
NEPT
16
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
| $17.1M | 1.39% |
3,846
-28
| -0.7% | -$140K |
|
17
Acadia Pharmaceuticals
ACAD
$4.47B
| $16.8M | 1.36% |
610,615
-116,014
| -16% | -$2.43M |
|
18
Madrigal Pharmaceuticals
MDGL
$12.5B
| $15M | 1.22% |
68,035
-8,915
| -12% | -$1.9M |
|
|
HNT
19
DELISTED
HEALTH NET INC
HNT
| $14.4M | 1.17% |
+453,780
| New | +$14.3M |
|
|
ARNA
20
PUT
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $13.5M | 1.09% |
+255,810
| New | +$17.2M |
|
21
Pacira BioSciences
PCRX
$1.05B
| $13.1M | 1.06% |
+272,034
| New | +$9.91M |
|
22
Sonida Senior Living
SNDA
$1.98B
| $13M | 1.05% |
40,939
-18,488
| -31% | -$6.27M |
|
|
COV
23
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
| $12.9M | 1.04% |
211,245
+135,105
| +177% | +$8.24M |
|
|
SNTS
24
DELISTED
SANTARUS INC
SNTS
| $12M | 0.98% |
532,243
-92,757
| -15% | -$2.21M |
|
|
CLVS
25
DELISTED
Clovis Oncology, Inc.
CLVS
| $11.8M | 0.96% |
194,701
+53,874
| +38% | +$3.82M |
|
Similar funds
BG
TAM
CIA
AC
EIC
CIC
CS
NC
Perceptive Advisors's Q3 2013 Portfolio in Review
As of Q3 2013, Perceptive Advisors held 137 positions worth $1.23B, up 24% from $992M the previous quarter. Its ten largest holdings account for 61% of the portfolio.
Perceptive Advisors deployed $116M of net new capital in Q3 2013, opening 51 new positions and adding to 28 existing holdings. Its largest new stake was ONYX PHARMACEUTICALS INC: 556,944 shares worth $69.5M.
By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 80% a quarter earlier, followed by Financials and Consumer Staples.
On the sell side, the largest reduction was Aegerion Pharmaceuticals, an estimated $106M trimmed.
- Perceptive Advisors's largest Q3 2013 buy was ONYX PHARMACEUTICALS INC: 556,944 shares worth $69.5M.
- Perceptive Advisors added most to Celgene Corp in Q3 2013, an estimated $37.6M increase.
- Perceptive Advisors's biggest Q3 2013 reduction was Aegerion Pharmaceuticals, cutting an estimated $106M.
- Perceptive Advisors fully exited Biogen in Q3 2013, selling an estimated $49.8M.
- Perceptive Advisors's ten largest holdings make up 61% of its $1.23B portfolio in Q3 2013.
- Perceptive Advisors opened 51 new positions and closed 23 in Q3 2013.
- Perceptive Advisors's portfolio value rose 24% quarter-over-quarter to $1.23B.
Based on Perceptive Advisors's 13F filing for Q3 2013, filed 14 Nov 2013.